Public Affairs Director Michael Capuano appeared on WGBH to comment on Super Tuesday. Capuano noted that changes in polling following one state’s primary often reflect a change in feeling rather than voting. “It’s pretty well known that a lot of people have been looking at this for a long time and haven’t really decided who they are going to vote for,” he said.
Capuano served as the U. S. Representative for Massachusetts’ 7th Congressional District from 1999 to 2019. He was a senior member of the Transportation and Infrastructure Committee and the Financial Services Committee, and chair of the Special Task Force on Ethics Enforcement, which resulted in the establishment of the Office of Congressional Ethics
Watch Capuano’s Super Tuesday commentary here, or listen here.
Capuano served as the U. S. Representative for Massachusetts’ 7th Congressional District from 1999 to 2019. He was a senior member of the Transportation and Infrastructure Committee and the Financial Services Committee, and chair of the Special Task Force on Ethics Enforcement, which resulted in the establishment of the Office of Congressional Ethics
Watch Capuano’s Super Tuesday commentary here, or listen here.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”